- Stock: Pre-Order
- Brand: Novo Nordisk
- Product ID: Insulin Degludec + Insulin Aspart Premixed
100% Secure Payment
bKash | Nagad | Cards via SSLCommerz | COD
Monthly Medicines Available | Free Delivery on Eligible Orders
This Item is for pre order
Ryzodeg Penfill – Insulin Degludec/Aspart 100 IU/ml Cartridge by Novo Nordisk
| Generic Name | Insulin Degludec / Insulin Aspart (IDegAsp) |
| Brand Name | Ryzodeg 70/30 Penfill |
| Manufacturer | Novo Nordisk A/S (Denmark) |
| Dosage Form | Solution for Injection — 3 ml Penfill Cartridge |
| Strength | 100 IU/ml (70 IU degludec + 30 IU aspart per ml) |
| Pack Size | 5 Penfill cartridges × 3 ml = 1,500 IU total |
| Drug Class | Co-formulation: Ultra-long Basal + Rapid-acting Insulin Analogue |
| Prescription Required | Yes — Rx Only |
| Onset / Duration | Aspart: onset 10–20 min | Degludec: duration >42 hrs (flat, peakless) |
What is Ryzodeg Penfill?
Ryzodeg 70/30 Penfill contains insulin degludec/aspart co-formulation — 70% ultra-long basal insulin degludec and 30% rapid-acting insulin aspart — in a 3 ml Penfill cartridge for compatible NovoPen reusable devices (NovoPen 4, 5, or Echo). The solution is clear — no rolling or resuspension required. Each cartridge contains 300 IU (210 IU degludec + 90 IU aspart). Preferred by patients using reusable pens for sustainability or requiring the NovoPen Echo's dose memory function.
Generic Name & Composition
Each ml contains 70 IU insulin degludec + 30 IU insulin aspart (both rDNA origin). These co-exist as separate molecules in a clear solution without interacting. After subcutaneous injection: degludec forms a multi-hexameric depot providing 42+ hour basal coverage; aspart is absorbed rapidly (10–20 min) for post-meal control. Each component follows its own independent pharmacokinetic pathway.
Indications
- Type 2 diabetes — once or twice daily injection covering basal and mealtime needs
- Patients using reusable NovoPen devices (NovoPen 4, 5, or Echo)
- Intensification from basal-only to basal-plus therapy
- Type 1 diabetes — in select cases under specialist guidance
How It Works — Mechanism of Action
Degludec (70%): Forms large soluble multi-hexameric subcutaneous depot; slowly releases monomers over 42+ hours — flat, peakless basal coverage. Aspart (30%): Rapid monomeric absorption (onset 10–20 min, peak 1–3 hrs, duration 3–5 hrs) — direct post-meal glucose control. Both activate insulin receptors: GLUT-4 glucose uptake, hepatic output suppression, glycogen synthesis.
Dosage & Administration
Regimen: Once or twice daily with main meal(s). Starting dose: 10 IU once daily with largest meal; titrate by 2 IU every 3–4 days. Penfill use: Load cartridge into compatible NovoPen device. Prime 2 IU. No rolling needed — solution is clear. Dial dose, inject subcutaneously, hold 6 seconds. Rotate sites.
Side Effects
Very common: Hypoglycaemia — from rapid aspart component (post-meal) and/or degludec component (overnight).
Common: Injection site reactions, lipohypertrophy, weight gain.
Uncommon: Lipoatrophy, peripheral oedema.
Rare: Anaphylaxis, severe allergic reactions.
Drug Interactions
Increase hypoglycaemia: Oral antidiabetics, GLP-1 agonists, SGLT-2 inhibitors, ACE inhibitors, MAO inhibitors, alcohol, salicylates.
Reduce effect: Corticosteroids, glucagon, thyroid hormones, thiazides, sympathomimetics, oral contraceptives.
Caution: Beta-blockers mask hypoglycaemia symptoms.
Contraindications
- Hypersensitivity to insulin degludec, aspart, or any excipient
- Active hypoglycaemia; for compatible reusable pen use only
Pregnancy & Lactation
Pregnancy: Limited data; specialist supervision required. Lactation: Not expected at clinically significant concentrations in breast milk.
Precautions & Warnings
- Clear solution — do NOT roll or shake. If cloudy, discard.
- NovoPen compatible devices only — NovoPen 4, 5, Echo.
- Eat within 15 minutes of injection.
- Degludec steady state: Full effect after 2–3 days. Avoid over-titration in first days.
Overdose
Prolonged hypoglycaemia (degludec extends risk beyond 42 hrs). Mild: oral glucose. Severe: IV dextrose or IM glucagon. Extended monitoring required.
Storage Instructions
- Unopened: 2–8°C. Do not freeze.
- In-use (loaded pen): Below 30°C. Do not refrigerate.
- Discard 56 days after first use.
Frequently Asked Questions (FAQs)
Q1: What is the difference between Ryzodeg Penfill and Ryzodeg FlexTouch?
Identical insulin — degludec 70 IU/ml + aspart 30 IU/ml. FlexTouch is pre-filled disposable. Penfill is a refill cartridge for NovoPen 4/5/Echo reusable devices.
Q2: Which pen devices work with Ryzodeg Penfill?
NovoPen 4, NovoPen 5, and NovoPen Echo. Confirm 3ml Penfill compatibility with your device manual.
Q3: Is Ryzodeg Penfill a clear or cloudy solution?
Clear. A solution, not a suspension — do not roll or shake. If cloudy or discoloured, do not use.
Q4: Who manufactures Ryzodeg Penfill?
Novo Nordisk A/S (Denmark).
⚕ Medical Disclaimer: For educational purposes only. Ryzodeg Penfill is Rx-only. Consult your diabetologist before changing insulin therapy. DiabetesStore.com.bd is a licensed online pharmacy.
